Dauphin-McKenzie Nathalie, Gilles Jerry M, Jacques Elvire, Harrington Thomas
Department of Obstetrics and Gynecology, University of Miami-Jackson Memorial Hospital, Miami, Florida, USA.
Obstet Gynecol Surv. 2006 May;61(5):343-52. doi: 10.1097/01.ogx.0000216976.15100.29.
Seventy-two thousand Americans are homozygous for the sickle cell gene and 2 million are carriers. The gene offers protection against malaria but can be a cause of chronic pain and early death. Life expectancy is 48 years for females. Some people with sickle cell anemia live into their 60s and beyond. The purpose of this article is to review and summarize evidence from clinical, translational, and epidemiologic studies that have examined the clinically relevant aspects of sickle cell anemia as it relates to the female patient. Studies were identified through a MEDLINE search for articles in English between the years 1966 and 2005. References from identified reports were also used to identify additional articles. Women with sickle cell disease experience multiple complications. These complications can affect each and every organ system and are often worse in pregnant women. Progestins, hydroxyurea, and bone marrow transplant appear to ameliorate sickle cell anemia. Other therapies being evaluated include those that increase fetal hemoglobin concentration and prevent dehydration of the sickle red blood cells. More than one third of pregnancies in women with sickle syndromes terminate in abortion, stillbirth, or neonatal death. Recently, a number of genes modifying the clinical severity of sickle cell anemia have been identified. Sickle anemia is associated with immense suffering and multisystemic complications. In addition to the now-established therapy with hydroxyurea and bone marrow transplants, there are multiple investigational treatments that offer the hope of extending life expectancy while diminishing associated morbidities. Whether any of these new agents are safe in pregnancy has yet to be determined.
Obstetricians & Gynecologists, Family Physicians.
After completion of this article, the reader should be able to summarize the multiple complications that women with sickle cell anemia (SCA) endure, explain that many of the complications worsen during pregnancy and increase the risk of an adverse pregnancy outcome, and state that there are treatment modalities that extend life and diminish morbidities.
7.2万美国人是镰状细胞基因的纯合子,200万人是携带者。该基因可提供抗疟疾保护,但可能导致慢性疼痛和早亡。女性的预期寿命为48岁。一些镰状细胞贫血患者可活到60多岁及更年长。本文的目的是回顾和总结临床、转化和流行病学研究的证据,这些研究考察了镰状细胞贫血与女性患者相关的临床相关方面。通过对1966年至2005年间英文文章的MEDLINE检索来识别研究。已识别报告的参考文献也用于识别其他文章。患有镰状细胞病的女性会经历多种并发症。这些并发症可影响每个器官系统,在孕妇中往往更严重。孕激素、羟基脲和骨髓移植似乎可改善镰状细胞贫血。正在评估的其他疗法包括那些可增加胎儿血红蛋白浓度并防止镰状红细胞脱水的疗法。患有镰状综合征的女性超过三分之一的妊娠以流产、死产或新生儿死亡告终。最近,已鉴定出一些改变镰状细胞贫血临床严重程度的基因。镰状贫血与巨大痛苦和多系统并发症相关。除了目前已确立的羟基脲和骨髓移植疗法外,还有多种研究性治疗方法有望延长预期寿命,同时减少相关发病率。这些新药在孕期是否安全尚未确定。
妇产科医生、家庭医生。
完成本文后,读者应能够总结患有镰状细胞贫血(SCA)的女性所承受的多种并发症,解释许多并发症在孕期会恶化并增加不良妊娠结局的风险,并指出存在可延长生命和减少发病率的治疗方式。